文献速递肾小球疾病

STARMEN试验:激素-环磷酰胺交替治疗优于他克莫司-利妥昔单抗序贯治疗原发性膜性肾病

The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
PubMed 文献 · Kidney Int · 2020-11-07

STARMEN随机开放标签对照试验纳入86例观察6个月后持续肾病综合征的原发性膜性肾病患者,比较6个月环磷酰胺-激素交替方案与他克莫司-利妥昔单抗序贯方案。24个月时激素-环磷酰胺组复合缓解率83.7%显著高于他克莫司-利妥昔单抗组58.1%(RR 1.44;95%CI 1.08-1.92),完全缓解率60%对26%(RR 2.36;95%CI 1.34-4.16),抗PLA2R抗体免疫应答率在3和6个月也更高。

要点

  • 激素-环磷酰胺交替方案24个月复合缓解率83.7%,优于他克莫司-利妥昔单抗的58.1%
  • 完全缓解率激素-环磷酰胺组60%显著高于他克莫司-利妥昔单抗组26%
  • 两组严重不良事件相似,但激素-环磷酰胺组抗PLA2R免疫应答更早更高

核心结论

  • 对于高危进展的原发性膜性肾病患者,6个月激素-环磷酰胺交替治疗在24个月诱导缓解方面优于他克莫司-利妥昔单抗序贯治疗。

研究设计与样本

  • 随机、开放标签、对照试验,纳入86例原发性膜性肾病且观察6个月后持续肾病综合征的患者,每组43例。

主要发现

  • 24个月复合缓解(完全或部分)激素-环磷酰胺组36例(83.7%),他克莫司-利妥昔单抗组25例(58.1%),相对风险1.44(95%CI 1.08-1.92)。
  • 24个月完全缓解激素-环磷酰胺组26例(60%),他克莫司-利妥昔单抗组11例(26%),相对风险2.36(95%CI 1.34-4.16)。
  • 抗PLA2R阳性患者免疫应答率在3个月和6个月时激素-环磷酰胺组分别为77%和92%,他克莫司-利妥昔单抗组分别为45%和70%,差异显著。
  • 复发激素-环磷酰胺组1例,他克莫司-利妥昔单抗组3例;严重不良事件两组相似。

临床怎么用

  • 对于持续肾病综合征的高危原发性膜性肾病患者,可优先考虑激素-环磷酰胺交替方案以获取更高的缓解率。

局限性

  • 开放标签设计可能引入偏倚;样本量较小(86例);随访24个月,长期结局未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with primary membranous nephropathy at high risk of progression. We hypothesized that sequential therapy with tacrolimus and rituximab is superior to cyclical alternating treatment with corticosteroids and cyclophosphamide in inducing persistent remission in these patients. This was tested in a randomized, open-label controlled trial of 86 patients with primary membranous nephropathy and persistent nephrotic syndrome after six-months observation and assigned 43 each to receive six-month cyclical treatment with corticosteroid and cyclophosphamide or sequential treatment with tacrolimus (full-dose for six months and tapering for another three months) and rituximab (one gram at month six). The primary outcome was complete or partial remission of nephrotic syndrome at 24 months. This composite outcome occurred in 36 patients (83.7%) in the corticosteroid-cyclophosphamide group and in 25 patients (58.1%) in the tacrolimus-rituximab group (relative risk 1.44; 95% confidence interval 1.08 to 1.92). Complete remission at 24 months occurred in 26 patients (60%) in the corticosteroid-cyclophosphamide group and in 11 patients (26%) in the tacrolimus-rituximab group (2.36; 1.34 to 4.16). Anti-PLA2R titers showed a significant decrease in both groups but the proportion of anti-PLA2R-positive patients who achieved immunological response (depletion of anti-PLA2R antibodies) was significantly higher at three and six months in the corticosteroid-cyclophosphamide group (77% and 92%, respectively), as compared to the tacrolimus-rituximab group (45% and 70%, respectively). Relapses occurred in one patient in the corticosteroid-cyclophosphamide group, and three patients in the tacrolimus-rituximab group. Serious adverse events were similar in both groups. Thus, treatment with corticosteroid-cyclophosphamide induced remission in a significantly greater number of patients with primary membranous nephropathy than tacrolimus-rituximab.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Fernández-Juárez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2020. PMID: 33166580. doi:10.1016/j.kint.2020.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。